Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Thermo Fisher Scientific Inc.. (6/2/14). "Press Release: Thermo Fisher Scientific and Nuclea Biotechnologies Collaborate to Accelerate Translation of Multiplexed Methods to Quantify Type 2 Diabetes Markers". Cambridge, MA.

Organisations Organisation BRIMS Center (Thermo Fisher)
  Group Thermo Fisher (Group)
  Organisation 2 Nuclea Biotechnologies Inc.
Products Product biomarker discovery services
  Product 2 TSQ Vantage™ triple-stage quadrupole mass spectrometer
Index term Index term Nuclea Biotechnologies–Thermo Fisher: mass spectrometry, 201406– collab biomarker quantification for Type 2 diabetes with BRIMS using triple quad MS
Persons Person Muraca, Patrick J. (Nuclea Biotechnologies 201309 CEO)
  Person 2 Lopez, Mary F. (Nuclea Biotechnologies 201502– COO before Thermo Fisher BRIMS + PerkinElmer + Proteome Systems)
     


Scientists at Nuclea Biotechnologies, Inc. and Thermo Fisher Scientific are pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs. Monitoring the levels of these markers may be useful in predicting the response to therapy for Type 2 diabetes.

Nuclea has extensive experience in developing and commercializing biomarkers and clinical tests. The Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has successfully collaborated with numerous leading clinical researchers to apply mass spectrometry (MS) to biomarker discovery and its translation to high-throughput, quantitative methods.

"We've already worked with the BRIMS Center to develop two other very important assays," said Nuclea CEO, Patrick Muraca. "These assays have demonstrated the sensitivity, precision and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins."

"The real-world application of multiplexed MS-based methods to Type 2 diabetes presents an opportunity to advance research in this crucial area." said Mary Lopez, director of the BRIMS Center, Thermo Fisher Scientific. "Nuclea's proven ability to validate and develop routine assays means our collaboration can support research efforts."

Scientists from Nuclea and the BRIMS Center will develop multiplexed MS-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations. A proprietary platform that combines Thermo Scientific MSIA immuno-enrichment technology, TSQ Vantage or Quantiva triple quadrupole mass spectrometers and Pinpoint Software will be used for the collaborative work.


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands - Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.


About Nuclea Biotechnologies, Inc.

Nuclea is headquartered in Pittsfield, Massachusetts with additional operations in Worcester and Cambridge, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries. http://www.nucleabio.com.

###

Contact:

Stu Matlow
Thermo Fisher Scientific
San Jose, Calif., USA
Phone: +1 408-965-6408
stu.matlow@thermofisher.com

Gregory M. D'Agostino, for Nuclea
Boston, Mass. USA
Phone: +1 617 695-0369
greg@libertysquaregroup.com

   
Record changed: 2016-03-19

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Thermo Fisher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Partnering Opens 560x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Partnering Opens 560x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px